Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacogenetics | 39 | 2023 | 434 | 12.920 |
Why?
|
Pharmacogenomic Testing | 14 | 2022 | 97 | 6.840 |
Why?
|
Carcinoma, Transitional Cell | 19 | 2023 | 164 | 5.790 |
Why?
|
Urologic Neoplasms | 16 | 2023 | 77 | 4.290 |
Why?
|
Precision Medicine | 15 | 2023 | 395 | 4.260 |
Why?
|
Urinary Bladder Neoplasms | 17 | 2024 | 383 | 3.320 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 7 | 2022 | 199 | 3.260 |
Why?
|
Pharmacogenomic Variants | 4 | 2021 | 41 | 2.310 |
Why?
|
Antineoplastic Agents | 22 | 2021 | 2360 | 2.290 |
Why?
|
Cisplatin | 17 | 2024 | 612 | 2.270 |
Why?
|
Decision Support Systems, Clinical | 5 | 2019 | 103 | 2.030 |
Why?
|
Perioperative Care | 6 | 2022 | 161 | 1.930 |
Why?
|
Drug Prescriptions | 5 | 2021 | 141 | 1.660 |
Why?
|
Immunoconjugates | 2 | 2022 | 106 | 1.620 |
Why?
|
Antibodies, Monoclonal | 12 | 2022 | 1376 | 1.590 |
Why?
|
Biomarkers, Tumor | 7 | 2022 | 1464 | 1.560 |
Why?
|
Neoplasms | 10 | 2022 | 2898 | 1.560 |
Why?
|
Clinical Decision-Making | 5 | 2021 | 257 | 1.540 |
Why?
|
Antimetabolites, Antineoplastic | 6 | 2020 | 236 | 1.490 |
Why?
|
Patient Portals | 2 | 2020 | 15 | 1.470 |
Why?
|
Humans | 115 | 2024 | 86644 | 1.390 |
Why?
|
Decision Support Techniques | 2 | 2021 | 160 | 1.380 |
Why?
|
Prescription Drugs | 2 | 2019 | 36 | 1.330 |
Why?
|
Antibodies, Monoclonal, Humanized | 12 | 2023 | 930 | 1.330 |
Why?
|
Anesthesiology | 2 | 2022 | 157 | 1.310 |
Why?
|
Genotype | 11 | 2023 | 1851 | 1.270 |
Why?
|
Polymorphism, Single Nucleotide | 8 | 2021 | 2357 | 1.260 |
Why?
|
Capecitabine | 6 | 2024 | 96 | 1.240 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 238 | 1.140 |
Why?
|
Practice Patterns, Physicians' | 5 | 2021 | 582 | 1.130 |
Why?
|
Aged, 80 and over | 26 | 2023 | 6509 | 1.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 508 | 1.070 |
Why?
|
Genomics | 5 | 2022 | 720 | 1.060 |
Why?
|
Cardiovascular Agents | 2 | 2015 | 56 | 1.010 |
Why?
|
Middle Aged | 45 | 2023 | 25028 | 1.000 |
Why?
|
Urothelium | 5 | 2023 | 70 | 0.980 |
Why?
|
Aged | 39 | 2024 | 18415 | 0.970 |
Why?
|
Prospective Studies | 12 | 2022 | 4214 | 0.970 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2016 | 878 | 0.940 |
Why?
|
Male | 50 | 2023 | 40966 | 0.910 |
Why?
|
Point-of-Care Systems | 3 | 2019 | 141 | 0.880 |
Why?
|
Female | 50 | 2023 | 44533 | 0.860 |
Why?
|
Tramadol | 1 | 2022 | 14 | 0.840 |
Why?
|
Germ-Line Mutation | 4 | 2020 | 329 | 0.830 |
Why?
|
Antineoplastic Agents, Immunological | 4 | 2020 | 185 | 0.830 |
Why?
|
Pain Management | 2 | 2021 | 127 | 0.830 |
Why?
|
Kidney Neoplasms | 5 | 2021 | 621 | 0.830 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2012 | 19 | 0.810 |
Why?
|
Busulfan | 2 | 2012 | 39 | 0.800 |
Why?
|
Adult | 36 | 2023 | 25648 | 0.800 |
Why?
|
Anesthetics | 1 | 2021 | 48 | 0.780 |
Why?
|
Platinum | 5 | 2023 | 63 | 0.780 |
Why?
|
B7-H1 Antigen | 9 | 2022 | 250 | 0.780 |
Why?
|
Rheumatology | 1 | 2021 | 28 | 0.770 |
Why?
|
Analgesics | 1 | 2021 | 119 | 0.750 |
Why?
|
Anesthesia | 1 | 2022 | 164 | 0.730 |
Why?
|
Carcinoma, Renal Cell | 3 | 2021 | 426 | 0.700 |
Why?
|
Drug Labeling | 2 | 2017 | 41 | 0.670 |
Why?
|
Information Dissemination | 1 | 2019 | 103 | 0.670 |
Why?
|
Medication Adherence | 1 | 2020 | 129 | 0.660 |
Why?
|
Drug Therapy | 2 | 2018 | 70 | 0.650 |
Why?
|
Pharmacology, Clinical | 1 | 2018 | 9 | 0.640 |
Why?
|
Quinazolines | 2 | 2016 | 220 | 0.620 |
Why?
|
Cardiovascular Diseases | 2 | 2015 | 827 | 0.620 |
Why?
|
Medical Order Entry Systems | 1 | 2017 | 25 | 0.600 |
Why?
|
Germ Cells | 2 | 2022 | 126 | 0.600 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 413 | 0.590 |
Why?
|
Follow-Up Studies | 11 | 2022 | 3640 | 0.590 |
Why?
|
Patient Care | 1 | 2018 | 100 | 0.580 |
Why?
|
Vidarabine | 3 | 2012 | 141 | 0.580 |
Why?
|
Genome, Human | 3 | 2019 | 756 | 0.570 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 23 | 0.570 |
Why?
|
Patient Education as Topic | 1 | 2019 | 351 | 0.570 |
Why?
|
Receptor, ErbB-3 | 1 | 2016 | 18 | 0.560 |
Why?
|
Fluorouracil | 2 | 2023 | 556 | 0.560 |
Why?
|
Critical Care | 1 | 2019 | 370 | 0.560 |
Why?
|
Physician's Role | 1 | 2017 | 179 | 0.530 |
Why?
|
Clinical Medicine | 1 | 2015 | 34 | 0.530 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 81 | 0.520 |
Why?
|
Collagen Type I | 1 | 2015 | 62 | 0.520 |
Why?
|
Cytochrome P-450 CYP2D6 | 3 | 2022 | 52 | 0.520 |
Why?
|
Snake Venoms | 2 | 2015 | 10 | 0.520 |
Why?
|
Physician-Patient Relations | 2 | 2019 | 610 | 0.520 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2014 | 176 | 0.520 |
Why?
|
Patient Selection | 3 | 2018 | 685 | 0.510 |
Why?
|
Academic Medical Centers | 2 | 2015 | 379 | 0.510 |
Why?
|
Programmed Cell Death 1 Receptor | 5 | 2022 | 159 | 0.500 |
Why?
|
Receptor, ErbB-2 | 1 | 2016 | 223 | 0.500 |
Why?
|
Genetic Predisposition to Disease | 4 | 2019 | 2271 | 0.480 |
Why?
|
Pyrroles | 2 | 2015 | 184 | 0.480 |
Why?
|
Inflammation | 1 | 2019 | 920 | 0.480 |
Why?
|
Transplantation Conditioning | 4 | 2014 | 373 | 0.470 |
Why?
|
Cardiology | 1 | 2015 | 123 | 0.460 |
Why?
|
Program Development | 1 | 2014 | 124 | 0.460 |
Why?
|
Ambulatory Care | 2 | 2014 | 181 | 0.460 |
Why?
|
Indoles | 2 | 2015 | 318 | 0.460 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 353 | 0.450 |
Why?
|
Hematologic Neoplasms | 4 | 2016 | 329 | 0.450 |
Why?
|
Biomarkers, Pharmacological | 1 | 2012 | 22 | 0.440 |
Why?
|
Mutation | 6 | 2020 | 3968 | 0.440 |
Why?
|
Nectins | 2 | 2022 | 9 | 0.440 |
Why?
|
Stomach Neoplasms | 1 | 2015 | 266 | 0.430 |
Why?
|
Cystectomy | 2 | 2024 | 102 | 0.420 |
Why?
|
Peptides | 1 | 2015 | 639 | 0.410 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 589 | 0.410 |
Why?
|
Neoplasm Staging | 7 | 2021 | 1939 | 0.400 |
Why?
|
Pharmaceutical Preparations | 1 | 2012 | 92 | 0.390 |
Why?
|
Prognosis | 12 | 2020 | 3679 | 0.390 |
Why?
|
Cell Adhesion Molecules | 2 | 2022 | 163 | 0.390 |
Why?
|
Patient Safety | 4 | 2023 | 212 | 0.390 |
Why?
|
Pain | 3 | 2022 | 391 | 0.380 |
Why?
|
Deoxycytidine | 1 | 2012 | 237 | 0.380 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 84 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2017 | 1313 | 0.370 |
Why?
|
Drug Delivery Systems | 1 | 2012 | 178 | 0.370 |
Why?
|
Hemoglobinopathies | 1 | 2010 | 10 | 0.370 |
Why?
|
Treatment Outcome | 17 | 2021 | 7993 | 0.370 |
Why?
|
Kidney Failure, Chronic | 2 | 2016 | 509 | 0.370 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2011 | 592 | 0.360 |
Why?
|
Carcinoma | 3 | 2021 | 436 | 0.360 |
Why?
|
Brain Neoplasms | 1 | 2015 | 763 | 0.360 |
Why?
|
Kidney Medulla | 1 | 2010 | 80 | 0.350 |
Why?
|
Quality of Life | 4 | 2022 | 1585 | 0.350 |
Why?
|
BK Virus | 1 | 2009 | 23 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 2438 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2019 | 1961 | 0.350 |
Why?
|
Polyomavirus Infections | 1 | 2009 | 28 | 0.350 |
Why?
|
Carboplatin | 6 | 2016 | 286 | 0.350 |
Why?
|
Hematuria | 1 | 2009 | 49 | 0.340 |
Why?
|
Tumor Virus Infections | 1 | 2009 | 81 | 0.340 |
Why?
|
Pyrimidines | 3 | 2018 | 370 | 0.340 |
Why?
|
Breast Neoplasms | 2 | 2020 | 2903 | 0.340 |
Why?
|
Benzamides | 2 | 2020 | 229 | 0.330 |
Why?
|
Warfarin | 2 | 2019 | 103 | 0.330 |
Why?
|
Disease Susceptibility | 1 | 2009 | 193 | 0.330 |
Why?
|
Genetic Testing | 4 | 2019 | 535 | 0.330 |
Why?
|
Genetic Variation | 3 | 2014 | 1351 | 0.320 |
Why?
|
Anemia, Sickle Cell | 1 | 2010 | 131 | 0.320 |
Why?
|
Neoplasm Metastasis | 6 | 2020 | 1056 | 0.310 |
Why?
|
Risk Assessment | 3 | 2021 | 2261 | 0.310 |
Why?
|
Surveys and Questionnaires | 3 | 2020 | 2501 | 0.310 |
Why?
|
Models, Genetic | 1 | 2012 | 926 | 0.300 |
Why?
|
Urinary Bladder | 3 | 2024 | 246 | 0.290 |
Why?
|
Cohort Studies | 4 | 2019 | 2767 | 0.290 |
Why?
|
Risk Factors | 5 | 2021 | 5417 | 0.280 |
Why?
|
Genotyping Techniques | 2 | 2018 | 68 | 0.280 |
Why?
|
Transplantation, Homologous | 7 | 2020 | 996 | 0.270 |
Why?
|
Neoplasm Invasiveness | 6 | 2024 | 552 | 0.270 |
Why?
|
Sirolimus | 1 | 2006 | 169 | 0.270 |
Why?
|
Kidney Diseases | 1 | 2009 | 418 | 0.260 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2019 | 865 | 0.260 |
Why?
|
Neuroendocrine Tumors | 1 | 2006 | 105 | 0.260 |
Why?
|
Kidney | 1 | 2011 | 1241 | 0.250 |
Why?
|
Tertiary Care Centers | 2 | 2016 | 94 | 0.250 |
Why?
|
Medical Oncology | 2 | 2022 | 359 | 0.240 |
Why?
|
Polymorphism, Genetic | 3 | 2015 | 819 | 0.240 |
Why?
|
Survival Analysis | 6 | 2023 | 1538 | 0.230 |
Why?
|
Angiogenesis Inhibitors | 2 | 2016 | 311 | 0.230 |
Why?
|
Neutropenia | 1 | 2023 | 215 | 0.230 |
Why?
|
Alemtuzumab | 3 | 2012 | 83 | 0.230 |
Why?
|
Hospitalization | 2 | 2019 | 849 | 0.220 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 72 | 0.220 |
Why?
|
Adenine Nucleotides | 2 | 2014 | 63 | 0.220 |
Why?
|
Arabinonucleosides | 2 | 2014 | 39 | 0.220 |
Why?
|
Chicago | 5 | 2015 | 1379 | 0.220 |
Why?
|
Thrombocytopenia | 1 | 2023 | 183 | 0.220 |
Why?
|
Fenretinide | 1 | 2002 | 2 | 0.220 |
Why?
|
Omeprazole | 1 | 2022 | 11 | 0.210 |
Why?
|
Succinylcholine | 1 | 2022 | 14 | 0.210 |
Why?
|
Ceramides | 1 | 2002 | 35 | 0.210 |
Why?
|
Hydralazine | 1 | 2022 | 20 | 0.210 |
Why?
|
Young Adult | 5 | 2019 | 5976 | 0.210 |
Why?
|
Practice Guidelines as Topic | 3 | 2018 | 1036 | 0.210 |
Why?
|
Sulfonamides | 2 | 2016 | 300 | 0.210 |
Why?
|
Oxycodone | 1 | 2022 | 35 | 0.210 |
Why?
|
Lymphocytes | 3 | 2010 | 464 | 0.200 |
Why?
|
Muscles | 1 | 2021 | 194 | 0.190 |
Why?
|
Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.190 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 26 | 0.190 |
Why?
|
Genome-Wide Association Study | 7 | 2012 | 1621 | 0.180 |
Why?
|
Pyrazines | 1 | 2020 | 92 | 0.180 |
Why?
|
Research | 2 | 2019 | 253 | 0.180 |
Why?
|
Disease-Free Survival | 6 | 2021 | 1204 | 0.180 |
Why?
|
Inpatients | 1 | 2022 | 297 | 0.180 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 1169 | 0.170 |
Why?
|
Drug Recalls | 1 | 2019 | 13 | 0.170 |
Why?
|
Codeine | 1 | 2019 | 12 | 0.170 |
Why?
|
Health Plan Implementation | 1 | 2019 | 56 | 0.170 |
Why?
|
Phenotype | 3 | 2019 | 2378 | 0.170 |
Why?
|
CREB-Binding Protein | 1 | 2018 | 16 | 0.170 |
Why?
|
E1A-Associated p300 Protein | 1 | 2018 | 11 | 0.170 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 1673 | 0.170 |
Why?
|
Pilot Projects | 2 | 2019 | 839 | 0.170 |
Why?
|
Acute Kidney Injury | 2 | 2014 | 295 | 0.170 |
Why?
|
Survival Rate | 3 | 2018 | 1863 | 0.170 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 418 | 0.170 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 429 | 0.170 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 1197 | 0.170 |
Why?
|
Patient Reported Outcome Measures | 1 | 2019 | 166 | 0.160 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 4 | 2021 | 56 | 0.160 |
Why?
|
Tumor Burden | 1 | 2019 | 289 | 0.160 |
Why?
|
Program Evaluation | 1 | 2019 | 297 | 0.160 |
Why?
|
United States | 5 | 2017 | 6672 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 375 | 0.160 |
Why?
|
Infusions, Intravenous | 3 | 2017 | 429 | 0.160 |
Why?
|
Radiosurgery | 1 | 2021 | 272 | 0.160 |
Why?
|
Guidelines as Topic | 1 | 2019 | 162 | 0.160 |
Why?
|
Abdominal Neoplasms | 1 | 2017 | 39 | 0.150 |
Why?
|
Pain, Postoperative | 1 | 2019 | 240 | 0.150 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 123 | 0.150 |
Why?
|
Tissue Donors | 1 | 2020 | 463 | 0.150 |
Why?
|
Standard of Care | 1 | 2017 | 79 | 0.150 |
Why?
|
Health Personnel | 1 | 2019 | 202 | 0.140 |
Why?
|
Hospital Mortality | 1 | 2019 | 349 | 0.140 |
Why?
|
Disease Management | 1 | 2019 | 327 | 0.140 |
Why?
|
Organoplatinum Compounds | 2 | 2019 | 94 | 0.140 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2016 | 8 | 0.140 |
Why?
|
User-Computer Interface | 1 | 2017 | 185 | 0.140 |
Why?
|
Social Perception | 1 | 2017 | 95 | 0.140 |
Why?
|
Anticoagulants | 1 | 2019 | 408 | 0.140 |
Why?
|
Safety | 1 | 2017 | 152 | 0.140 |
Why?
|
Chemoradiotherapy | 1 | 2018 | 301 | 0.140 |
Why?
|
Immunotherapy | 2 | 2020 | 629 | 0.140 |
Why?
|
Benzodioxoles | 1 | 2015 | 16 | 0.140 |
Why?
|
Attitude to Health | 1 | 2017 | 220 | 0.130 |
Why?
|
Case-Control Studies | 1 | 2020 | 1805 | 0.130 |
Why?
|
Universities | 2 | 2013 | 135 | 0.130 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 56 | 0.130 |
Why?
|
5' Untranslated Regions | 1 | 2015 | 49 | 0.130 |
Why?
|
Transcription Factor RelA | 1 | 2015 | 49 | 0.130 |
Why?
|
Adolescent | 7 | 2023 | 8981 | 0.130 |
Why?
|
G(M2) Ganglioside | 1 | 2015 | 3 | 0.130 |
Why?
|
Tay-Sachs Disease | 1 | 2015 | 6 | 0.130 |
Why?
|
Communication | 1 | 2019 | 441 | 0.130 |
Why?
|
Response Elements | 1 | 2015 | 63 | 0.130 |
Why?
|
Forecasting | 1 | 2016 | 304 | 0.130 |
Why?
|
Tunica Intima | 1 | 2015 | 59 | 0.130 |
Why?
|
Area Under Curve | 2 | 2014 | 334 | 0.130 |
Why?
|
Epilepsies, Myoclonic | 1 | 2015 | 13 | 0.130 |
Why?
|
Fatal Outcome | 1 | 2015 | 293 | 0.130 |
Why?
|
Ureter | 1 | 2016 | 92 | 0.130 |
Why?
|
Maximum Tolerated Dose | 2 | 2017 | 270 | 0.130 |
Why?
|
Nomograms | 1 | 2014 | 28 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 559 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 636 | 0.120 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 297 | 0.120 |
Why?
|
Electronic Health Records | 1 | 2017 | 319 | 0.120 |
Why?
|
Kidney Transplantation | 2 | 2016 | 849 | 0.120 |
Why?
|
Exome | 1 | 2014 | 127 | 0.120 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 111 | 0.120 |
Why?
|
Liver Neoplasms | 2 | 2017 | 736 | 0.120 |
Why?
|
Neoadjuvant Therapy | 1 | 2016 | 318 | 0.120 |
Why?
|
Genetic Markers | 1 | 2014 | 476 | 0.120 |
Why?
|
Radiography | 1 | 2015 | 813 | 0.110 |
Why?
|
Total Quality Management | 1 | 2013 | 34 | 0.110 |
Why?
|
Software | 1 | 2017 | 654 | 0.110 |
Why?
|
Receptors, Cell Surface | 1 | 2014 | 286 | 0.110 |
Why?
|
Muscle Neoplasms | 1 | 2013 | 18 | 0.110 |
Why?
|
Endonucleases | 1 | 2012 | 21 | 0.110 |
Why?
|
Workflow | 1 | 2013 | 77 | 0.110 |
Why?
|
Endothelium, Vascular | 1 | 2015 | 435 | 0.110 |
Why?
|
Fanconi Anemia | 1 | 2012 | 7 | 0.110 |
Why?
|
Genetics, Medical | 1 | 2013 | 52 | 0.110 |
Why?
|
Databases, Factual | 1 | 2016 | 814 | 0.110 |
Why?
|
Delivery of Health Care | 1 | 2017 | 426 | 0.110 |
Why?
|
DNA Repair | 1 | 2014 | 356 | 0.110 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2022 | 456 | 0.110 |
Why?
|
Lymphocyte Depletion | 1 | 2012 | 97 | 0.110 |
Why?
|
Biopsy | 2 | 2016 | 1163 | 0.110 |
Why?
|
Biomedical Research | 2 | 2013 | 376 | 0.110 |
Why?
|
Models, Statistical | 1 | 2016 | 574 | 0.110 |
Why?
|
Atherosclerosis | 1 | 2015 | 244 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 1686 | 0.100 |
Why?
|
Blood Glucose | 1 | 2016 | 873 | 0.100 |
Why?
|
Disease Progression | 3 | 2016 | 1531 | 0.100 |
Why?
|
Time Factors | 3 | 2016 | 5210 | 0.100 |
Why?
|
Fibroblasts | 1 | 2015 | 729 | 0.100 |
Why?
|
T-Lymphocytes | 2 | 2022 | 1195 | 0.100 |
Why?
|
Graft vs Host Disease | 2 | 2012 | 365 | 0.100 |
Why?
|
Melphalan | 1 | 2011 | 98 | 0.100 |
Why?
|
Decision Making | 1 | 2017 | 642 | 0.100 |
Why?
|
HLA Antigens | 1 | 2012 | 232 | 0.100 |
Why?
|
Population Groups | 1 | 2010 | 41 | 0.100 |
Why?
|
Metabolic Clearance Rate | 1 | 2010 | 121 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 183 | 0.100 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 55 | 0.100 |
Why?
|
Postoperative Complications | 2 | 2016 | 2207 | 0.090 |
Why?
|
Population Surveillance | 1 | 2012 | 219 | 0.090 |
Why?
|
Liver | 2 | 2014 | 1230 | 0.090 |
Why?
|
Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.090 |
Why?
|
Graft Rejection | 2 | 2016 | 1065 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2012 | 381 | 0.090 |
Why?
|
Drug Combinations | 1 | 2010 | 224 | 0.090 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 154 | 0.090 |
Why?
|
Vinca Alkaloids | 1 | 2009 | 3 | 0.090 |
Why?
|
Anthracyclines | 1 | 2009 | 37 | 0.090 |
Why?
|
Cell Line | 5 | 2011 | 2468 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2011 | 468 | 0.090 |
Why?
|
Down-Regulation | 1 | 2010 | 504 | 0.080 |
Why?
|
DNA | 1 | 2014 | 1294 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2009 | 138 | 0.080 |
Why?
|
Haplotypes | 1 | 2010 | 642 | 0.080 |
Why?
|
Creatinine | 1 | 2009 | 338 | 0.080 |
Why?
|
Cell Proliferation | 2 | 2010 | 1578 | 0.080 |
Why?
|
Genetics, Population | 1 | 2010 | 394 | 0.070 |
Why?
|
Fatigue | 2 | 2022 | 174 | 0.070 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 1208 | 0.070 |
Why?
|
Neurons | 1 | 2015 | 1546 | 0.070 |
Why?
|
Incidence | 1 | 2010 | 1577 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 806 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 977 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 916 | 0.060 |
Why?
|
Kidney Function Tests | 2 | 2016 | 123 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 744 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 3362 | 0.060 |
Why?
|
Indazoles | 2 | 2016 | 68 | 0.060 |
Why?
|
Models, Biological | 1 | 2011 | 1749 | 0.060 |
Why?
|
Hyperparathyroidism | 1 | 2003 | 67 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 1052 | 0.060 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2023 | 29 | 0.060 |
Why?
|
Cell Line, Tumor | 3 | 2016 | 2426 | 0.060 |
Why?
|
Parathyroidectomy | 1 | 2003 | 78 | 0.060 |
Why?
|
Pharmacists | 1 | 2022 | 32 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2014 | 155 | 0.050 |
Why?
|
Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
Sphingolipids | 1 | 2002 | 20 | 0.050 |
Why?
|
Alleles | 2 | 2017 | 1128 | 0.050 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 55 | 0.050 |
Why?
|
Glomerular Filtration Rate | 2 | 2016 | 384 | 0.050 |
Why?
|
Morpholines | 1 | 2002 | 65 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2021 | 2705 | 0.050 |
Why?
|
Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
Age Factors | 2 | 2020 | 1851 | 0.050 |
Why?
|
Drug Synergism | 1 | 2002 | 303 | 0.050 |
Why?
|
Immunity, Cellular | 1 | 2022 | 177 | 0.050 |
Why?
|
DNA Damage | 1 | 2023 | 366 | 0.050 |
Why?
|
Gene Fusion | 1 | 2021 | 38 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 54 | 0.050 |
Why?
|
Bone Marrow Transplantation | 1 | 2001 | 286 | 0.050 |
Why?
|
Blood Transfusion | 1 | 2001 | 157 | 0.050 |
Why?
|
Antibodies, Viral | 1 | 2022 | 293 | 0.050 |
Why?
|
Risk | 2 | 2012 | 674 | 0.050 |
Why?
|
Hodgkin Disease | 1 | 2001 | 177 | 0.050 |
Why?
|
Vaccination | 1 | 2022 | 254 | 0.050 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 1041 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 1721 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.040 |
Why?
|
Cell Survival | 1 | 2002 | 969 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2023 | 1823 | 0.040 |
Why?
|
Allografts | 1 | 2020 | 172 | 0.040 |
Why?
|
Hematopoiesis | 1 | 2020 | 163 | 0.040 |
Why?
|
Gene Expression | 2 | 2015 | 1284 | 0.040 |
Why?
|
Blood Platelets | 1 | 2019 | 149 | 0.040 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 85 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.040 |
Why?
|
Retreatment | 1 | 2017 | 107 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2017 | 31 | 0.040 |
Why?
|
Internationality | 1 | 2017 | 69 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2017 | 153 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 339 | 0.040 |
Why?
|
Remission Induction | 1 | 2018 | 722 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2017 | 122 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 526 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 78 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 372 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2016 | 66 | 0.030 |
Why?
|
Cholesterol, Dietary | 1 | 2015 | 27 | 0.030 |
Why?
|
Transplants | 1 | 2016 | 40 | 0.030 |
Why?
|
E-Selectin | 1 | 2015 | 30 | 0.030 |
Why?
|
Carotid Artery Injuries | 1 | 2015 | 22 | 0.030 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2015 | 38 | 0.030 |
Why?
|
1-Deoxynojirimycin | 1 | 2015 | 3 | 0.030 |
Why?
|
Glycoside Hydrolase Inhibitors | 1 | 2015 | 2 | 0.030 |
Why?
|
Receptors, LDL | 1 | 2015 | 53 | 0.030 |
Why?
|
RNA Polymerase II | 1 | 2015 | 55 | 0.030 |
Why?
|
Netrin Receptors | 1 | 2014 | 6 | 0.030 |
Why?
|
Lentivirus | 1 | 2015 | 36 | 0.030 |
Why?
|
Protein Interaction Mapping | 1 | 2015 | 82 | 0.030 |
Why?
|
Primary Cell Culture | 1 | 2015 | 72 | 0.030 |
Why?
|
Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2016 | 176 | 0.030 |
Why?
|
Transplant Recipients | 1 | 2016 | 122 | 0.030 |
Why?
|
Microsomes, Liver | 1 | 2014 | 49 | 0.030 |
Why?
|
Recurrence | 2 | 2011 | 1139 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2015 | 153 | 0.030 |
Why?
|
Transgenes | 1 | 2015 | 180 | 0.030 |
Why?
|
Plasmids | 1 | 2015 | 287 | 0.030 |
Why?
|
Reference Standards | 1 | 2014 | 159 | 0.030 |
Why?
|
Ireland | 1 | 2013 | 9 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 572 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 165 | 0.030 |
Why?
|
Nephrectomy | 1 | 2016 | 294 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2015 | 439 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 159 | 0.030 |
Why?
|
Transplantation Chimera | 1 | 2012 | 80 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2018 | 8489 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2015 | 428 | 0.030 |
Why?
|
Graft Survival | 1 | 2016 | 884 | 0.030 |
Why?
|
United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
Students | 1 | 2013 | 147 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2011 | 20 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2016 | 1753 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2015 | 937 | 0.030 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 503 | 0.030 |
Why?
|
Orchiectomy | 1 | 2011 | 68 | 0.030 |
Why?
|
Transplantation, Autologous | 2 | 2003 | 331 | 0.030 |
Why?
|
Contrast Media | 1 | 2016 | 1078 | 0.020 |
Why?
|
Computational Biology | 1 | 2014 | 528 | 0.020 |
Why?
|
Action Potentials | 1 | 2015 | 573 | 0.020 |
Why?
|
Genes, X-Linked | 1 | 2011 | 37 | 0.020 |
Why?
|
Insulin | 1 | 2016 | 1160 | 0.020 |
Why?
|
Diarrhea | 1 | 2011 | 182 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2015 | 1924 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2015 | 1135 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 859 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 227 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2015 | 2818 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2010 | 114 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.020 |
Why?
|
Registries | 1 | 2013 | 702 | 0.020 |
Why?
|
Quality Improvement | 1 | 2013 | 428 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 314 | 0.020 |
Why?
|
Laparoscopy | 1 | 2016 | 754 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 3092 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2014 | 1801 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2015 | 1458 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 532 | 0.020 |
Why?
|
Transcription Factors | 1 | 2015 | 1565 | 0.020 |
Why?
|
Child | 2 | 2012 | 6927 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 1373 | 0.020 |
Why?
|
Physicians | 1 | 2013 | 673 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 1384 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2011 | 763 | 0.020 |
Why?
|
Biomarkers | 1 | 2011 | 1718 | 0.020 |
Why?
|
Baltimore | 1 | 2001 | 36 | 0.010 |
Why?
|
Mice | 1 | 2015 | 11352 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2001 | 1019 | 0.010 |
Why?
|
Animals | 1 | 2015 | 26582 | 0.010 |
Why?
|